Clinical trials: DDI (Drug-Drug Interaction)
Healthy
A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Digoxin (P-Glycoprotein Substrate) in Healthy Participants
The main purpose of this study is to evaluate the effect of Pirtobrutinib (LOXO-305) on multiple oral doses of digoxin (P-gp substrate) when administered as single and multiple doses by collecting the blood samples and conducting…
- Trial name
- NCT06194214
- Testing
- Pirtobrutinib, Digoxin
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Musculoskeletal Pain
A Phase 1 Clinical Trial DHP2306R1 and DHP2306R2 in Healthy Adult Volunteers
This phase 1 study is to evaluate the safety and pharmacokinetic drug interactions of DHP2306R1 and DHP2306R2 when administered alone and in combination in healthy conditions.
- Trial name
- NCT06395155
- Testing
- DHP2306R1, DHP2306R2
- Where
- South Korea
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Daehwa Pharmaceutical Co., Ltd.
Type 2 Diabetes Mellitus
A Study to Evaluate the DDI of HSK7653 With Metformin
This is a Phase 1, single center, open-label, single arm, drug-drug interaction study of HSK7653 and metformin in Healthy Subjects.
- Trial name
- NCT06084156
- Testing
- HSK7653, Metformin
- Where
- China
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Diabetes Mellitus Type 2
CKD-396 Drug-drug Interaction Study(B) (CKD-396 DDI(B) P1)
The purpose of this study is to evaluate a pharmacokinetic drug interaction between sitagliptin and lobeglitazone in healthy male volunteers.
- Trial name
- NCT02827890
- Testing
- Januvia Tab. 100mg, Januvia Tab. 100mg + Duvie Tab. 0.5mg
- Where
- South Korea
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Healthy
Evaluation and Validation of Metabolic Markers for the Assessment of CYP3A Activity and Prediction of DDI
Evaluation and validation of metabolic markers for the assessment of CYP3A activity and prediction of drug-drug interaction in Korean healthy subjects.
- Trial name
- CYP3A_weak (NCT02328443)
- Testing
- Midazolam, itraconazole, rifampicin
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Healthy
Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants
This study will evaluate the potential drug interactions between ALXN2050 and cyclosporine (Part 1), between ALXN2050 and tacrolimus (Part 2), and between ALXN2050 and mycophenolate mofetil (MMF) (Part 3).
- Trial name
- NCT05202145
- Testing
- ALXN2050, Cyclosporine, Tacrolimus
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Alexion Pharmaceuticals, Inc.
HCV Infection
Drug-Drug Intercations and Direct Acting Antiviral Agents Against HCV
Background: Currently used direct-acting antivirals (DAA) share pharmacokinetic pathways with many comedications commonly used in patients with chronic hepatitis C virus (HCV) infection, therefore drug-drug interactions (DDI)…
- Trial name
- NCT06928259
- Where
- 4 sites in Spain
- Volunteers
- 728 people
- Sponsor
- University of Seville
Drug Drug Interaction (DDI)
to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban
to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban
- Trial name
- NCT07265466
- Testing
- JP-1366 and clopidogrel, JP-1366 and aspirin, JP-1366 and atorvastatin
- Where
- South Korea
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Onconic Therapeutics Inc.
HIV Infections
DDI HV (ATV - Merck)
The purpose of this study is to to assess the effect of ATV 300 mg BID on the PK of raltegravir 400 mg BID, to assess the effect of raltegravir 400 mg BID on the PK of ATV 300 mg BID, and to assess the ECG effects of ATV 300 mg…
- Trial name
- NCT00518297
- Testing
- Raltegravir, Atazanavir, Atazanavir + Raltegravir
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Drug Interaction Potentiation
Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 50mg
Healthy male volunteers were administered alone and in combination with dapoxetine 30mg mirodenafil 50mg for three times, respectively and the pharmacokinetic interaction was compared between the two drugs.
- Trial name
- NCT02485028
- Testing
- Dapoxetine 30mg tablet, Mirodenafil 50mg tablet
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Healthy Volunteers
Dexpramipexole and Warfarin Drug Drug Interaction (DDI) Study
This study will assess the effect of dexpramipexole on the pharmacokinetics (PK) of the CYP2C9 probe substrate warfarin in healthy volunteers.
- Trial name
- NCT01597310
- Testing
- Warfarin, Dexpramipexole
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Knopp Biosciences
Sarcoma, Kaposi, HIV Infections
The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma
Primary: To evaluate the safety, toxicity, and antitumor activity of two doses of interferon alfa-2b (IFN-alpha) combined with a fixed dose of didanosine (ddI) in patients with Kaposi's sarcoma associated with HIV infection.
- Trial name
- NCT00001114
- Testing
- Interferon alfa-2b, Didanosine
- Where
- 13 sites in United States, Puerto Rico
- Volunteers
- 90 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Drug Drug Interaction
Drug-Drug Interaction (DDI) Study in Healthy Volunteers
A Phase 1, Open Label, Fixed Sequence Study to Evaluate the Effect of BLD-0409 on the Single Dose Pharmacokinetics of a Cocktail of Probe Substrates for CYP450 Enzymes in Healthy Volunteers
- Trial name
- NCT04814498
- Testing
- Geneva Cocktail, BLD-0409
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Blade Therapeutics
Healthy
A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Different Formulations of Midazolam in Healthy Participants
The main purpose of this study is to assess the effect of Pirtobrutinib (LOXO-305) on how fast different formulations of midazolam gets into the blood stream and how long it takes the body to remove it when administered in…
- Trial name
- NCT06180967
- Testing
- Midazolam Syrup, Midazolam Solution, Pirtobrutinib
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Eosinophilic Esophagitis
A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab
The purpose of this study to evaluate the potential for disease-mediated drug-drug interactions between cendakimab and selected substrates of metabolic enzymes in eosinophilic esophagitis participants.
- Trial name
- NCT05175352
- Testing
- Cendakimab, CYP substrates
- Where
- 12 sites in United States
- Volunteers
- 16 people
- Sponsor
- Celgene
Dermatitis Atopic
An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates
This is an open-label, single group, 2-period, Phase 1, single-sequence study. The study duration will be up to 342 days. The treatment period will be up to Week 29, where Week 29 is defined as End of Treatment (last amlitelimab…
- Trial name
- NCT06686628
- Testing
- Amlitelimab, Midazolam, Caffeine
- Where
- Germany
- Volunteers
- 23 people
- Sponsor
- Sanofi
Healthy
A Study of Nipocalimab With Co-administration of Etanercept or Hydroxychloroquine in Healthy Participants
The primary purpose of this study is to assess the effect of nipocalimab on the pharmacokinetic (PK) of etanercept (Part 1); and to assess the effect of hydroxychloroquine (HCQ) on total serum immunoglobin G (IgG) reduction by…
- Trial name
- NCT04973566
- Testing
- Nipocalimab, Etanercept, Hydroxychloroquine
- Where
- Netherlands
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy Adult Subjects
A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone
This study will assess the potential for clinical drug-drug interactions between omaveloxolone and a number of substrates and inhibitors of metabolic enzymes and drug transporters.
- Trial name
- NCT04008186
- Testing
- Omaveloxolone, Midazolam oral solution, Repaglinide 1 MG
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Biogen
Drug Interaction Potentiation
Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 100mg
Healthy male volunteers were administered alone and in combination with dapoxetine 30mg mirodenafil 100mg for three times, respectively and the pharmacokinetic interaction was compared between the two drugs.
- Trial name
- NCT02485041
- Testing
- Dapoxetine 30mg, Mirodenafil 100mg
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Healthy Adult Subject, Overweight Subject
A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.
The purpose of this study is to characterize the effect of HDM1002 on the PK of single dose of repaglinide, atorvastatin, digoxin and rosuvastatin in healthy adult subjects.
- Trial name
- NCT06601517
- Testing
- Repaglinide, Atorvastatin, Digoxin
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.